Erenumab
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Trade Name | Aimovig |
---|---|
Common Name | Erenumab |
Indication | migraine disorders |
Drug Class | Monoclonal antibodies: fully human, neural indications |
